Combined Hormonal Contraception during Breastfeeding-A Survey of Physician's Recommendations.

breastfeeding combined hormonal contraception progesterone-only pill

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
15 Nov 2023
Historique:
received: 26 09 2023
revised: 09 11 2023
accepted: 13 11 2023
medline: 25 11 2023
pubmed: 25 11 2023
entrez: 25 11 2023
Statut: epublish

Résumé

Until breastfeeding is established, progesterone-only pill (POP) use is preferable over combined hormonal contraception (CHC), as the latter potentially reduces milk production. Yet, POPs are often associated with breakthrough bleeding (BTB), and irregular spotting is often a reason for their cessation. Conversely, CHC is less associated with BTB but is not usually prescribed, even if breastfeeding has been established, despite its verified safety profile. Here, we surveyed physicians' perception of CHC safety during breastfeeding through an online questionnaire (N = 112). Physicians were asked if they would prescribe CHC to a woman three months postpartum, breastfeeding fully, and suffering from BTB while using POPs. Half of the physicians responded they would, 28% would not until six months postpartum, while 14% would not during breastfeeding. Of the physicians that would prescribe CHC, 58% would without any reservation, 24% would only after discussing milk reduction with the patient, 9% would use a pill with a lower hormonal dose, and 9% would only prescribe CHC 3 months postpartum. The main risk associated with CHC during breastfeeding, as perceived by physicians, is a potential decrease in breast milk production (88%). While some physicians consider CHC unsafe during breastfeeding, most health organizations consider CHC compatible with breastfeeding 5-6 weeks after birth. Thus, there is a gap in the attitude and knowledge of physicians about the safety profile of CHC, and only half acknowledge that the risk of BTB justifies the use of CHC instead of POPs while breastfeeding three months postpartum. We highlight the importance of physician's education, advocate CHC breastfeeding compatibility if breastfeeding has been established (i.e., 30 days postpartum), and underline the importance of discussing the option of CHC with patients in case POPs have unwanted side effects.

Identifiants

pubmed: 38002722
pii: jcm12227110
doi: 10.3390/jcm12227110
pmc: PMC10671995
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Ann Trop Paediatr. 1992;12(2):203-9
pubmed: 1381897
Contraception. 1978 Feb;17(2):131-9
pubmed: 630883
Cochrane Database Syst Rev. 2015 Oct 12;(10):CD001329
pubmed: 26457821
Hum Reprod. 1996 Oct;11 Suppl 2:20-3
pubmed: 8982741
Contraception. 1986 Aug;34(2):169-75
pubmed: 3780231
Breastfeed Med. 2023 Feb;18(2):84-85
pubmed: 36720088
Cochrane Database Syst Rev. 2002;(1):CD003517
pubmed: 11869667
PLoS One. 2020 Aug 20;15(8):e0237067
pubmed: 32817664
Am J Clin Nutr. 1980 Apr;33(4):816-24
pubmed: 7361700
Contraception. 2016 Sep;94(3):262-74
pubmed: 26002804
Am J Obstet Gynecol. 2023 Oct 21;:
pubmed: 37871872
Am J Obstet Gynecol. 2017 Feb;216(2):129-134
pubmed: 27776920
Contraception. 1984 Dec;30(6):505-22
pubmed: 6241559
J Obstet Gynaecol India. 2016 Oct;66(Suppl 1):335-9
pubmed: 27651626
J Clin Med. 2022 Jun 13;11(12):
pubmed: 35743459
Eur J Contracept Reprod Health Care. 2012 Apr;17(2):128-34
pubmed: 22200109
Contraception. 1982 Mar;25(3):243-52
pubmed: 6804162
Cochrane Database Syst Rev. 2015 Mar 20;(3):CD003988
pubmed: 25793657
Eur J Contracept Reprod Health Care. 1997 Jun;2(2):105-11
pubmed: 9678098
J Altern Complement Med. 2011 Feb;17(2):139-42
pubmed: 21261516
Epilepsy Behav. 2022 Apr;129:108627
pubmed: 35240507
Arch Womens Ment Health. 2016 Apr;19(2):409-13
pubmed: 25956588
Breastfeed Med. 2023 Sep;18(9):645-665
pubmed: 37672571
Obstet Gynecol. 2012 Jan;119(1):5-13
pubmed: 22143258

Auteurs

Lior Segev (L)

Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
PUAH Institute: Fertility, Medicine, Halacha, Jerusalem 9547735, Israel.

Gideon Weitzman (G)

PUAH Institute: Fertility, Medicine, Halacha, Jerusalem 9547735, Israel.

Goldie Katz-Samson (G)

Nishmat: The Jeanie Schottenstein Center for Advanced Torah Study for Women, Jerusalem 9328249, Israel.

Abraham O Samson (AO)

Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.

Guy Shrem (G)

IVF Unit, Department of Obstetrics and Gynecology, Kaplan Medical Center, Rehovot 7610001, Israel.

Naama Srebnik (N)

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
IVF Unit, Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.

Classifications MeSH